Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIC Vaccine Lot Consistency Study in Older Adults
NCT06482359Phase 3Withdrawn
- Sponsor
- Novavax
- Start
- Feb 2025
- Primary completion
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, single-blind trial of qNIV + CoV2373 in coronavirus disease 2019 (COVID-19) and influenza (4 arms), sponsored by Novavax. Primary endpoints: Solicited Local and Systemic Adverse Events, Unsolicited Adverse Events and Medically Attended Adverse Events and 1 more. Planned start Feb 2025; status: withdrawn.
02
Drugs
qNIV + CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT06482359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06482359.